Table 4: Overview on how to decide to optimize personalized medicine for P2Y12 inhibitors per patient.

Number of platelet function tests for P2Y12 inhibitor that shows
NPRHPR How is the patient treated with current APT? What to do with the APT?

617098.tab.00430Well treatedCurrent APT can be continued
21Well treatedCurrent APT can be continued
12UndertreatedSwitch APT; consider
 (i) Clinical characteristics
 (ii) Comedication
 (iii) Genetics
03UndertreatedSwitch APT; consider:
 (i) Clinical characteristics
 (ii) Comedication
 (iii) Genetics

NPR: normal on-treatment platelet reactivity; HPR: high on-treatment reactivity; APT: antiplatelet therapy.